Roche Finds Antibody Effective Against Solid Tumors
Posted on: Thursday, 25 October 2007, 06:00 CDT
Roche has announced positive results from the Phase I trial of a human monoclonal antibody to target IGF-1R, in patients with solid tumors. The IGF-1R pathway plays an important role in mediating the resistance to cytotoxic drugs and EGFR/HER2-targeted agents.
In the Phase I study, R1507 was administered by intravenous infusion. Nine of 34 adult patients with advanced solid tumors experienced disease stabilization. Four of the seven heavily pretreated patients with Ewing's sarcoma demonstrated clinical benefit with two of these patients achieving durable, objective partial responses.
A weekly administration of R1507 was well tolerated with very few side effects. Treatment with R1507 was also not associated with the typical side-effects normally observed with cancer therapy.
Stephen Leong, assistant professor of medical oncology at the University of Colorado Cancer Center, said: "This drug attacks the IGF pathway and may provide a new class of drugs to treat a variety of cancers, including breast, prostate, colon, melanoma, myeloma and a variety of sarcomas, which could greatly add to the way that we currently treat these patients."
Based on these initial results with R1507, Roche plans to conduct additional trials and work with a global consortium of sarcoma experts, including the Sarcoma Alliance for Research through Collaboration (SARC).
Source: Datamonitor
Related Articles
- Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
- Phase I Results Announced for R1507 From Genmab's Collaboration With Roche
- Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
- ARIAD Initiates Phase 3 'Succeed' Trial of Oral Deforolimus in Patients With Metastatic Sarcomas
- Ariad Reaches Agreement With FDA for Phase III Cancer Drug Trial
- ARIAD Announces Agreement With FDA on Special Protocol Assessment for Phase 3 Clinical Trial of Oral Deforolimus
- Interim Phase 2 Data Show Sustained Clinical Benefit in Advanced Sarcoma Patients Treated With ARIAD's mTOR Inhibitor, AP23573; Results Highlighted at the AACR-NCI-EORTC News Briefing on New Oncology Drugs
- ARIAD Reports Positive Early Phase 2 Results on AP23573, Novel mTOR Inhibitor, in Patients With Advanced Sarcomas at ASCO; Data Show Clinical Benefit and Symptomatic Improvement
- Jejunal Free-Flap Reconstruction Complicated By Development of Post- Irradiation Sarcoma: What Information Should Patients Receive About the Long-Term Effects of Radiotherapy for Head and Neck Tumours?
- Myeloid Sarcoma Involving the Breast
 |
 |
User Comments (0)
RSS Feeds